Ruti Aga's Six-Year Ban: The Forged Prescription, the Vanished Clinic, and the Drug the Report Filed in the Wrong Drawer

Six years. That is the first number the Athletics Integrity Unit's Thursday statement puts in front of you. But the document that decided those six years was not a laboratory report. It was a prescription slip — for a knee injury — stamped by a clinic that did not exist, issued by a 'doctor' who was a family member with no medical registration on record.

I have spent three decades going through Indian youth athletics paperwork: entry lists, result sheets, selection circulars, Khelo India participation data. In this case I went looking for a race sheet and came back with a prescription pad. I went looking for a name and found a filing cabinet.

And there is a technical correction that has to come first, because it changes the case. The coverage called methylprednisolone a 'prohibited steroid' and placed it in WADA's performance-enhancing category. That is imprecise. The substance is a glucocorticoid — class S9 on the WADA Prohibited List — and S9 drugs are prohibited in-competition only, via injection, oral or rectal routes. Once you fix that classification, the question changes from 'why did she take a steroid' to 'why did she not use the legal route for that injection'.

Context: a career recorded in documents

Ruti Aga is an Ethiopian marathoner, 32 years old. Her record includes the 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors. The source gives no personal best. My older result sheets have Berlin 2026 second place at roughly 2:18:34 and Tokyo 2026 first at roughly 2:20:40; those figures need checking against primary sheets before I would print them as fixed facts. What the source does establish is her class: a 2:18–2:20 marathoner, globally competitive, and one of more than a dozen such names in Ethiopia's domestic depth.

The case begins at a half marathon in China in March. The report does not name the race, her time, or the field strength. It says only that she won it and that a sample collected there tested positive. One inference is unavoidable: that race was almost certainly a World Athletics Label event with an elite women's field and in-competition testing, otherwise no AIU sample would exist. I am flagging that as inference, not fact.

The year of the March race is also not stated. The statement says she has been provisionally suspended since 10 September and the ban is dated from the same day — that is procedure, not leniency. The missing year is the old problem I have fought for years: federation statements do not treat dates as compulsory, and two decades later a historian is left guessing. Two decades of youth records do not digitize themselves — the scale here is one case, the failure is the same.

The framework is explicit: World Athletics Anti-Doping Rules, enforced by the AIU, applying the WADA Code (2026) and the WADA Prohibited List. Two charges were established. Presence of a prohibited substance, two years. Tampering — producing a forged prescription and a misleading explanation in interview — four years. Six in total.

Core: the class of drug is the real hinge

In anti-doping cases the drug class is not a technicality; it is the foundation of the entire defence. Here the coverage filed it in the wrong drawer.

Anabolic steroids (S1) are prohibited at all times — in competition, out of competition, everywhere. Glucocorticoids (S9) are different. They are prohibited in-competition only. A therapeutic knee injection given mid-block can be entirely lawful. It becomes a violation only when residues are present in a sample taken in competition.

That is where timing enters, and it is the point every account skips. A road race's testing window opens at 23:59 the day before the race. An injection given a few days earlier can still be detectable, however therapeutic the intent. The real question in S9 cases is therefore not 'what was taken' but 'when, by which route, and was it documented'.

And a documented route existed: a Therapeutic Use Exemption. An athlete with a chronic knee, a medical file and a team physician either holds a TUE or applies for one, or at minimum chooses a treatment route that avoids the prohibited one. Aga's case shows no trace of any of that — and the absence of a trace explains the forgery. When the real paperwork does not exist, the athlete manufactures it.

The arithmetic: two and four

The sanction architecture is standard, not exceptional. Two years for presence, consistent with a specified substance finding where intent was not proven. Four years for tampering, the Code's standard penalty. That the total is six tells us the panel rejected the no-significant-fault mitigation that would otherwise have reduced the presence sanction.

There is a paradox here worth naming. Forged documentation is itself circumstantial evidence of concealment intent, yet it did not escalate the presence sanction; it sat alongside it as a separate charge. The panel's logic appears to be that the drug case and the paper case are distinct. They were added, not merged.

Nor is the 10 September start a discount. Time served under provisional suspension counts against the ban. It is a procedural benefit, not a reduction.

Three verification failures

The statement's details break into three independent failures, all pointing the same way.

First, the clinic. The institution named on the prescription did not exist. That is not a filing error; it is a missing institution.

Second, the 'doctor'. The person who issued it was a family member with no medical registration. This is where the case stops being individual carelessness and becomes a picture of a system: a team with no credentialed physician in it at all.

Third, the 'old pad'. The person claimed to have used an old prescription pad from a former workplace. The clinic explicitly disowned the claim. The last layer of the defence was also made of paper, and that paper tore.

Taken together the picture is clear and uncomfortable: this is not a drug-abuse case, it is a medical-governance vacuum. A 32-year-old elite marathoner whose income depends on racing, carrying a knee problem, lands in a network where the doctor comes from the family and the prescription comes from an old pad.

The knee is the root cause; the forgery is a symptom

Chronic knee pathology is not an exception among marathoners; it is an occupational risk. Weekly loading of 180–200km, two or three Majors a year, Asian label races in between — that sequence breaks knees first. Intra-articular or peri-articular methylprednisolone is standard sports-medicine practice for such cases. That is exactly why the knee explanation sounds physiologically plausible.

But plausibility and proof are different things. A patient who was genuinely treated has a record: a hospital receipt, a doctor's name, a date, a dose. With a real record, the defence runs on the real record; a forged prescription is the strongest available evidence that no real record existed.

This is where an old habit of mine intrudes. Injury-and-return stories romanticize load management, when in practice it is often the polite name for making room for commercial races and exhibition events. In marathon running it takes a blunt form: skipping a race means skipping an appearance fee, and the appearance fee is the income that carries the whole year between Majors.

The appearance-fee economy meets the testing economy

The least-discussed and most important part of the case begins here.

For East African marathoners, the Chinese label circuit is a distinct income tier: less prestige than a Major, a good appearance fee, lower risk, three or four races a season. For a 2:18–2:20 runner it bridges the gaps between Majors.

But that same circuit is now the AIU's highest-yield hunting ground. Where the fees are large, the elite fields are deep; where the elite fields are deep, there is testing. The appearance-fee economy and the testing economy are now colliding in the same races, and the athlete stands in the middle of the collision.

In the language of a transfer window, the real story here is not the headline. It is that the people who run this career — agent, manager, camp 'doctor' — appear on no document. The statement names only the family member who made the prescription. Whether an agent or management was investigated is not stated.

Career arithmetic: 32 to 38

The ban runs six years from 10 September. Return age is roughly 38. The 2028 Olympic cycle is closed to her entirely — a timeline fact, not a moral judgement.

Against Ethiopia's women's marathon depth, the ban is functionally a lifetime one. Where an entire sub-2:16 generation is waiting, a 38-year-old returning with a doping record does not enter the national selection conversation whatever the clock says. That is not discrimination; it is the arithmetic of depth.

There is a further split worth recording. The 2026 Tokyo title and three Major second places predate the March race. Absent a finding of earlier use, those results are not automatically annulled. But the report does not state the disqualification scope, and that is where the largest gap in the information sits.

Standard AIU practice would void the result and prize money from the race where the sample was collected, along with ranking points accrued after that date. I am stating that as inference; the report does not say it.

The sentence I do not have

As a performance analyst I have to record that there is no performance data here at all. No time, no splits, no field depth, no weather. 'She won' cannot be converted into form — beyond the fact that she was in shape good enough to win at that level. Where the record is empty, the analyst's job is to write zero, not to guess.

It reminds me of the weakness in my own method. When I watched the 2026 Tokyo race on screen, I had a split sheet open and noted that Aga's strength lay in holding even pace through the last ten kilometres. That sentence is still true. It is simply not this article's subject. I catalogued the fragments before I trusted the legend; this time the fragments belonged to a prescription pad.

Effect on the competitive landscape: nil

This needs saying plainly, because many reports inflate the significance here. The ban has no measurable effect on Ethiopia's medal capacity. Her three Major second places were commercial-tier results, not championship conversions. One runner's removal does not register in national-team arithmetic.

The real subject is governance. And there is a pattern I have tracked for several years: among AIU road-running cases involving East African athletes, a large share involve a second violation layered on the first — a changed story, a fabricated document, a misleading interview. The enforcement frontier has shifted from detection to document verification. Aga's case belongs to that family; it is not an outlier.

The argument nobody prints

Two camps are resting on the same mistake. Those who say six years is harsh for a steroid start from a false premise: it was not a steroid. And those who say the AIU targets African road runners should look at the arithmetic: four of the six years are for the paper, not the drug. Paper is a choice, not a chemistry.

Those who say the knee injury explains everything hold half a truth. The injury explains the injection; it cannot explain the forgery. And the one defence that could have worked — route, timing and documented authorization — is the one the forged slip closed off.

What changes next

One thing is certain: this statement was written for coaches and state associations, not for spectators. For them it carries an expensive lesson rather than a cheap one. What a TUE is, how long a drug given by a particular route stays detectable, when a competition's testing window opens — that knowledge is no longer a luxury for medical staff. It is a licensing condition.

The second question remains unanswered: who advised the forgery? The statement names only a family member. The entourage that accepted or suggested the slip appears in no file. If it stays out of the file, the next athlete in that camp, with that same knee, will have the same slip made — and the system will hand down another six years. The question then will be who was punished: the athlete whose career ended, or the system that handed her the route. The rulebook arrived before the athlete did. The question is who turned its pages.